ImmunoPrecise, LiteVax begin preclinical studies of SARS-CoV-2 vaccine

By The Science Advisory Board staff writers

September 25, 2020 -- ImmunoPrecise and LiteVax have commenced preclinical SARS-CoV-2 vaccine trials.

The vaccine design is based on large datasets obtained during the analysis of ImmunoPrecise Antibodies' (IPA) SARS-CoV-2 therapeutic programs, which the firm has used to craft its spike protein variant vaccine candidates.

The candidates are combined with a novel class of synthetic carbohydrate derivatives with the final formulations aimed at high efficacy and low adverse effects, the firms said.

The preclinical study is ongoing at the Institute of Agrifood Research and Technology (IRTA) in Catalonia, Spain, and is focusing on a single, low-dose administration. In tandem, IPA and LiteVax are starting ex vivo assays, with study results expected by November 2020. From there, the companies will be able to prioritize which vaccine candidates to develop further.

However, it should be noted the companies are not making any claims that the vaccine has the ability to eliminate, cure, or contain SARS-CoV-2 at this time.

ImmunoPrecise subsidiary expands B cell Select platform
IPA Europe, a subsidiary of ImmunoPrecise Antibodies, has expanded its foundational B cell Select platform for seamless integration into ImmunoPrecise's...
ImmunoPrecise, Zymeworks partner on SARS-CoV-2 antibody
ImmunoPrecise and Zymeworks announced that they have formed a research collaboration to develop a multispecific SARS-CoV-2 antibody.
Immunoprecise highlights combo neutralization of antibodies
Immunoprecise Antibodies has conducted additional characterization of a subset of fully human, therapeutic SARS-CoV-2 antibodies that are potent and exhibit...
ImmunoPrecise identifies SARS-CoV-2 neutralizing antibodies
ImmunoPrecise Antibodies has identified several lead candidate antibodies with high neutralizing activity in vitro that are being manufactured for further...
ImmunoPrecise, NIH, Integrated Biotherapeutics test antibodies for COVID-19
ImmunoPrecise Antibodies announced that it is collaborating with the National Institute of Diabetes and Digestive and Kidney Diseases at the National...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter